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havior and menstrual symptoms dimensions were excluded
because of conceptual issues. In the future, they will be
presented as optional modules. The analyses identified a
new structural model applicable to pre, peri and post-
menopausal women. The new WHQ is made of a 23-
item core questionnaire which investigates 6 domains:
anxiety/depressed mood, well-being, somatic symptoms,
memory/concentration, vasomotor symptoms, and sleep
problems. The cross-sectional psychometric properties of
the 23-item WHQ in each country were good and found
to be better than those obtained using the 37-item ver-
sion. CONCLUSIONS: At this stage, the 23-item WHQ
can be used in international trials to assess the impact of
condition, disease or treatment on emotional and physi-
cal well-being of women. Its reproducibility and respon-
siveness to change over time need to be documented.
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In a large Phase III double-blind randomised clinical trial,
the CAPRIE study (clopidogrel versus aspirin in Patients
at Risk of Ischemic Events), two anti-platelet agents were
compared in secondary prevention of ischemic events
(myocardial infarction, ischemic stroke, vascular death)
in atherothrombotic patients. The study was not de-
signed to collect health economic parameters. OBJEC-
TIVES: we needed to assess the incremental cost-effec-
tiveness ratio of the new anti-platelet agent in the main
European countries and to test various hypotheses.
METHODS: Clinical outcomes: A Markov model de-
signed with several clinical states combined the rates of
all ischemic events (fatal and non fatal, primary and sub-
sequent) reported in the CAPRIE study. The rates of ad-
verse events were also taken into account. Survival data:
the remaining life expectancy of the patients who experi-
enced an event was not directly estimated from the CAP-
RIE study as the mean follow-up of the patients was only
two years. The survival estimates was approached by
identifying, in the Framingham study, cohorts of patients
similar to the CAPRIE patients. Resources use and costs:
decision trees about inpatient and outpatient manage-
ment of myocardial infarctions and ischemic strokes were
built from available data (literature, data base, expert
opinion) and were locally validated. RESULTS: The eco-
nomic model allowed to calculate the incremental cost-
effectiveness ratio of the new anti-platelet agent for the
basic scenario (CAPRIE study) and for other scenarios
(changes of the time horizon, considering that the com-
parator could not be the reference treatment for all the
patients in a real life situation, high risk patients analy-
sis). CONCLUSION: Because they are protocol driven,
the Phase III double-blind randomised clinical trials do
not usually reflect what would happen in the real life.
Modeling, which allows to perform simulations, could be
a way of correcting.
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BACKGROUND: The development of an economic
model to assess antipsychotics for first episode schizo-
phrenia raised several issues: (i) clinical and economic ev-
idence relates to chronic schizophrenia; (ii) inconsistent
reporting of outcomes and adverse events; (iii) compari-
son of costs and outcomes across several interventions is
complicated by (a) an absence of head to head compari-
sons (b) intolerance or resistance to 3 plus antipsychotics.
OBJECTIVES: To design a decision analytic model to
evaluate the relative efficiency of antipsychotics. METH-
ODS: Two composite variables were defined to incorpo-
rate 23 efficacy and safety events: (i) acceptable treat-
ment (able/willing to continue allocated therapy, with/
without side effects or symptom control) (ii) unaccept-
able treatment (unacceptable side effects or symptom
control, non compliance). Utility values were defined for
each variable. Clinical data were extracted from system-
atic reviews separately for first episode and chronic
schizophrenia. Age specific resource use data were esti-
mated from national statistics to proxy first episode pa-
tients. Follow on therapy for people failing first therapy
was estimated by (i) specifying drug sequence; (ii) treat-
ing follow on therapy as a random event. Monte Carlo
simulation analysis was used to reduce complexity and
incorporate uncertainty. RESULTS: It was not possible
to identify consistent data for first episode patients only.
Interpretation of the specific treatment sequences was
complex with 32 possible combinations identified. There
were substantial differences within classes of antipsychot-
ics. The results were sensitive to: (i) specification of fol-
low on therapy (ii) distributional form applied to data.
CONCLUSIONS: The analysis highlighted the poor
quality and absence of relevant data. This could not be
dealt with by modelling. Current classifications of typical
and atypical antipsychotics may not be relevant.
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Osteoporosis is a major public health problem becoming
increasingly important as our population ages. Approxi-
mately one in two women will experience an osteoporotic
fracture in their lifetime. Additionally, millions have low
bone mass that increases fracture risk. OBJECTIVE: To
develop a methodology, in a managed care environment,
that identifies members at high-risk for osteoporotic frac-
tures. METHODS: This was a retrospective database
study. The study population was from a Midwest health
plan of 1.38 million lives. The database consisted of all
pharmaceutical, professional, and institutional claims
linked at the patient level. The study population was
identified by the following criteria: continuously enrolled
from 7/1/95 to 3/31/99, complete coverage, individuals
older than age 45 for women and age 65 for men with
fracture of interest, specific fracture by site; hip (820.0 to
821.39), vertebrae (806 to 806.91), and forearm (813.0
to 813.9x), past history of fracture and specific site by V
codes (13.5 and 15.5), chronic users of steroids (180
days exposure over a period of 24 months), history of
transplant (by CPT-4 and V codes), a diagnosis code of
733.0x, current history (in study period) of ICD-9 codes
for pathologic fractures 733.1 to 733.19, a family history
of musculoskeletal disease (V code 17.8), and individuals
with bone density studies (by CPT-4 codes). RESULTS:
Over 120 million claims were screened to stratify the
population (prior to 1997) into risk bands. We used
2,000 patients with current osteoporotic fractures to de-
velop and to verify a predictive model of fracture risk.
CONCLUSIONS: A claims based model identified high-
risk patients for fractures. Application of the model to
1999 data generated a list of patients for intervention.
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Economic models for highly active antiretroviral (HAART)
drug regimens used in HIV infection differ from other
models in that they must accommodate the results of
short trials, but yield relatively long-reaching predictions
of health outcomes, resource use, and costs, in an envi-
ronment where valid epidemiologic data are scarce. Stan-
dard Markov models were effective for short survival
times. With improved treatment options, survival of HIV
patients has been prolonged significantly. A methodolog-
ical consequence is that Markov models with fixed tran-
sition probabilities may no longer be reliable. Further-
more, the number and disparity of outcomes of interest,
such as surrogate marker changes, primary health out-
comes, treatment side effects, degree of adherence, and
viral resistance to subsequent regimens complicate Markov
approaches. OBJECTIVE: To compare two possible so-
lutions:1) a system of linked, staged Markov models; and
2) a hierarchical Monte Carlo simulation. METHODS:
Application of both methods to existing data. FIND-
INGS: The data requirement for the staged Markov sys-
tem depends on whether transitions are derived empiri-
cally or from theory. We found that approximately 27
exposure years are required per health state to ensure sta-
ble incidence densities, and that 12 model states health
states can capture both risk of progression and risk of
events observed in about 1500 patients over 3 years, but
that stable transition rates require at least 50 exposure
years per health state, and vary by antiretroviral experi-
ence. The hierarchical Monte Carlo model has more
modest requirements for data density, but depends on
long streams of uninterrupted observations from unique
patients. The strengths and weaknesses of these two ap-
proaches will be illustrated with data from the ritonavir
and ABT378 trials.
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Within pharmacoeconomic analysis, the generalizability
of results from one jurisdiction to another should not be
presumed. In general re-analysis of data for specific juris-
dictions is required. Thus, the lack of transparency in the
reporting of evaluations can limit their applicability to
decision-making. OBJECTIVES: First, to build a decision
analytic model to replicate the results from a stochastic
analysis of a US trial based economic analysis. Second, to
assess the transferability and generalizability of results to
the Canadian setting. METHODS: A decision analysis
model was developed to replicate results from the US
trial comparing the use of basiliximab and cyclosporin to
placebo and cyclosporin for renal transplant patients. We
determined the necessary parameters required to replicate
the study results and conducted re-analysis for the Cana-
dian setting. Data required related to clinical probabili-
ties, costs of treatments and treatment paths. RESULTS:
Results from the US study were replicated using the deci-
sion analytic model. The cyclosporin-basiliximab arm led
to the least cost path when compared to cyclosporin-pla-
cebo, with costs of $28,858 and $32,253 respectively,
approximating the results of the stochastic analysis of
$28,927 and $32,300. Further analysis was conducted
for the Canadian setting, and found similar results.
CONCLUSIONS: Where the criteria for geographic
transferability are satisfied it is possible to transfer the re-
sults of a clinical trial to other geographic locations.
However, it need not follow that results are generaliz-
able. In addition, when assessing the generalizability of
